Notably, Nordmann et al. reported an EMPD tumor harboring the ERBB2 S310F mutation that was sensitive to anti-HER2 treatment, with the patient achieving a near-complete response by a combination treatment of trastuzumab and carboplatin [24]. This evidence concerns the gene ERBB2 and neoplasm.